...modulator in Salix, two years after Biogen decided to return its rights to the compound. Salix Pharmaceuticals Ltd.... ...receives an undisclosed upfront payment, and is eligible for development and regulatory milestones, plus royalties. Salix... ...from University of California Los Angeles (see "Salix Licenses New NASH Target from UCLA" ). Salix...
...with a license from UCLA to a compound against a new target in the space. Salix Pharmaceuticals Ltd.... ...non-alcoholic steatohepatitis, non-alcoholic fatty liver disease and other gastrointestinal and liver diseases. The program is Salix's... ...showed that activating ADCYAP1R1 increased satiety and lean mass while suppressing appetite and fat accumulation. Salix...
...The Salix Pharmaceuticals Ltd. subsidiary of Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) and partner Norgine B.V. (Amsterdam, the... ...an NDA for Plenvu (NER1006) for bowel cleansing. The new PDUFA date is May 13. Salix...
...NYSE:ABBV) acquired Pharmacyclics Inc. for $21 billion; and Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) acquired Salix Pharmaceuticals Ltd....
...to $23.86 on Tuesday after media reports said it was discussing a sale of its Salix... ...has held discussions about "various divestitures including but not limited to Salix." Since Valeant acquired Salix... ...its stock closed at $173.26 in New York (see BioCentury Extra, March 16, 2015) .
Chris Lieu
Salix Pharmaceuticals Ltd.
Valeant...
...modulator in Salix, two years after Biogen decided to return its rights to the compound. Salix Pharmaceuticals Ltd.... ...receives an undisclosed upfront payment, and is eligible for development and regulatory milestones, plus royalties. Salix... ...from University of California Los Angeles (see "Salix Licenses New NASH Target from UCLA" ). Salix...
...with a license from UCLA to a compound against a new target in the space. Salix Pharmaceuticals Ltd.... ...non-alcoholic steatohepatitis, non-alcoholic fatty liver disease and other gastrointestinal and liver diseases. The program is Salix's... ...showed that activating ADCYAP1R1 increased satiety and lean mass while suppressing appetite and fat accumulation. Salix...
...The Salix Pharmaceuticals Ltd. subsidiary of Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) and partner Norgine B.V. (Amsterdam, the... ...an NDA for Plenvu (NER1006) for bowel cleansing. The new PDUFA date is May 13. Salix...
...NYSE:ABBV) acquired Pharmacyclics Inc. for $21 billion; and Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) acquired Salix Pharmaceuticals Ltd....
...to $23.86 on Tuesday after media reports said it was discussing a sale of its Salix... ...has held discussions about "various divestitures including but not limited to Salix." Since Valeant acquired Salix... ...its stock closed at $173.26 in New York (see BioCentury Extra, March 16, 2015) .
Chris Lieu
Salix Pharmaceuticals Ltd.
Valeant...